PURPOSE: 68Ga-labeled 1,4,7,10-tetraazacyclododecane-N,N',N″,N‴-tetraacetic acid-d-Phe1-Tyr3-octreotide (68Ga-DOTATOC) is taken up by activated macrophages, which accumulate in active inflammatory lesions. The purpose of this study was to investigate the feasibility of 68Ga-DOTATOC PET/CT for assessment of vulnerable plaque, by evaluating correlation between aortic uptake of 68Ga-DOTATOC and cardiovascular risk factors. METHODS: Fifty patients with neuroendocrine tumors who underwent 68Ga-DOTATOC PET/CT were retrospectively enrolled. The uptakes in the thoracic aorta were measured by two methods: multi-sample region-of-interest (ROI) method and single volume-of-interest (VOI) method. TBRmax-avg, TBRmean-avg, TBRmax-VOI, and TBRmean-VOI were defined by maximum and mean target-to-background ratio (TBR) from the multi-sample ROI method and the single VOI method, respectively. RESULTS: Framingham risk score (FRS) exhibited significant correlations with TBRmax-avg and TBRmean-avg, as well as TBRmax-VOI (r = 0.3389-0.4593, P < 0.05 for all). TBRmax-avg and TBRmax-VOI were significantly higher in high FRS group than in low FRS group (1.48 ± 0.21 vs. 1.70 ± 0.17, P < 0.001 for TBRmax-avg and 1.90 ± 0.33 vs. 2.25 ± 0.36, P = 0.002 for TBRmax-VOI). TBR exhibited high correlations between the two measuring methods (r = 0.9684, P < 0.001 for TBRmean-avg and TBRmean-VOI and r = 0.8681, P < 0.001 for TBRmax-avg and TBRmax-VOI). CONCLUSIONS: 68Ga-DOTATOC uptake in the thoracic aorta exhibited a significant correlation with cardiovascular risk factors, which suggests the feasibility of 68Ga-DOTATOC PET for vulnerable plaque imaging, with a simple measurement of the single VOI method that is comparable to the multi-sample ROI-based approach.
PURPOSE: 68Ga-labeled 1,4,7,10-tetraazacyclododecane-N,N',N″,N‴-tetraacetic acid-d-Phe1-Tyr3-octreotide (68Ga-DOTATOC) is taken up by activated macrophages, which accumulate in active inflammatory lesions. The purpose of this study was to investigate the feasibility of 68Ga-DOTATOC PET/CT for assessment of vulnerable plaque, by evaluating correlation between aortic uptake of 68Ga-DOTATOC and cardiovascular risk factors. METHODS: Fifty patients with neuroendocrine tumors who underwent 68Ga-DOTATOC PET/CT were retrospectively enrolled. The uptakes in the thoracic aorta were measured by two methods: multi-sample region-of-interest (ROI) method and single volume-of-interest (VOI) method. TBRmax-avg, TBRmean-avg, TBRmax-VOI, and TBRmean-VOI were defined by maximum and mean target-to-background ratio (TBR) from the multi-sample ROI method and the single VOI method, respectively. RESULTS: Framingham risk score (FRS) exhibited significant correlations with TBRmax-avg and TBRmean-avg, as well as TBRmax-VOI (r = 0.3389-0.4593, P < 0.05 for all). TBRmax-avg and TBRmax-VOI were significantly higher in high FRS group than in low FRS group (1.48 ± 0.21 vs. 1.70 ± 0.17, P < 0.001 for TBRmax-avg and 1.90 ± 0.33 vs. 2.25 ± 0.36, P = 0.002 for TBRmax-VOI). TBR exhibited high correlations between the two measuring methods (r = 0.9684, P < 0.001 for TBRmean-avg and TBRmean-VOI and r = 0.8681, P < 0.001 for TBRmax-avg and TBRmax-VOI). CONCLUSIONS: 68Ga-DOTATOC uptake in the thoracic aorta exhibited a significant correlation with cardiovascular risk factors, which suggests the feasibility of 68Ga-DOTATOC PET for vulnerable plaque imaging, with a simple measurement of the single VOI method that is comparable to the multi-sample ROI-based approach.
Authors: Catarina Malmberg; Rasmus S Ripa; Camilla B Johnbeck; Ulrich Knigge; Seppo W Langer; Jann Mortensen; Peter Oturai; Annika Loft; Anne Mette Hag; Andreas Kjær Journal: J Nucl Med Date: 2015-10-01 Impact factor: 10.057
Authors: James H F Rudd; Kelly S Myers; Sameer Bansilal; Josef Machac; Ash Rafique; Michael Farkouh; Valentin Fuster; Zahi A Fayad Journal: J Am Coll Cardiol Date: 2007-08-13 Impact factor: 24.094
Authors: Axel Rominger; Tobias Saam; Eva Vogl; Christopher Ubleis; Christian la Fougère; Stefan Förster; Alexander Haug; Paul Cumming; Maximilian F Reiser; Konstantin Nikolaou; Peter Bartenstein; Marcus Hacker Journal: J Nucl Med Date: 2010-01-15 Impact factor: 10.057
Authors: Ralph B D'Agostino; Ramachandran S Vasan; Michael J Pencina; Philip A Wolf; Mark Cobain; Joseph M Massaro; William B Kannel Journal: Circulation Date: 2008-01-22 Impact factor: 29.690
Authors: Axel Rominger; Tobias Saam; Sarah Wolpers; Clemens C Cyran; Michael Schmidt; Stefan Foerster; Konstantin Nikolaou; Maximilian F Reiser; Peter Bartenstein; Marcus Hacker Journal: J Nucl Med Date: 2009-09-16 Impact factor: 10.057
Authors: James H F Rudd; Kelly S Myers; Sameer Bansilal; Josef Machac; Cathy Anne Pinto; Christopher Tong; Ash Rafique; Richard Hargeaves; Michael Farkouh; Valentin Fuster; Zahi A Fayad Journal: J Nucl Med Date: 2008-05-15 Impact factor: 10.057
Authors: Jason M Tarkin; Francis R Joshi; Nicholas R Evans; Mohammed M Chowdhury; Nichola L Figg; Aarti V Shah; Lakshi T Starks; Abel Martin-Garrido; Roido Manavaki; Emma Yu; Rhoda E Kuc; Luigi Grassi; Roman Kreuzhuber; Myrto A Kostadima; Mattia Frontini; Peter J Kirkpatrick; Patrick A Coughlin; Deepa Gopalan; Tim D Fryer; John R Buscombe; Ashley M Groves; Willem H Ouwehand; Martin R Bennett; Elizabeth A Warburton; Anthony P Davenport; James H F Rudd Journal: J Am Coll Cardiol Date: 2017-04-11 Impact factor: 24.094
Authors: Jacob K Jensen; Emilie H Zobel; Bernt J von Scholten; Viktor Rotbain Curovic; Tine W Hansen; Peter Rossing; Andreas Kjaer; Rasmus S Ripa Journal: Front Endocrinol (Lausanne) Date: 2021-11-30 Impact factor: 5.555
Authors: Andrej Ćorović; Christopher Wall; Justin C Mason; James H F Rudd; Jason M Tarkin Journal: Curr Cardiol Rep Date: 2020-08-09 Impact factor: 3.955